1:06 PM
 | 
Apr 24, 2019
 |  BC Extra  |  Financial News

Why Satsuma investors see room for another migraine therapy

While a new class of drugs has captured most of the attention around migraine treatments, Satsuma's investors believe there's room in the marketplace for a new formulation of an old drug.

Satsuma Pharmaceuticals Inc. (South San Francisco, Calif.) said Wednesday it had raised a $62 million series B round to fund a Phase III trial of STS101, its dry powder formulation of dihydroergotamine (DHE) and intranasal delivery system, to treat acute migraine. The placebo-controlled study is to begin in 3Q19.

Wellington Management led the round. Also participating were existing backers RA Capital,...

Read the full 439 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >